You are here: Industry Insights > Regenxbio

News List

Regenxbio Announces Pipeline Expansion with RGX-181 americanpharmaceuticalreview
August 31, 2018
Regenxbio announced it is developing a new product candidate, RGX-181, for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidas
REGENXBIO to Develop New Product contractpharma
August 31, 2018
REGENXBIO announced it is developing a new product candidate, RGX-181, for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidas
Regenxbio’s wet AMD gene therapy shows promise in phase 1 fiercebiotech
August 09, 2018
Regenxbio reported promising interim data from a phase 1 trial of its gene therapy for wet age-related macular degeneration (AMD). The treatment.....
Regenxbio to buy battered Dimension for gene therapies biospectrumasia
August 29, 2017
Under the terms of the definitive agreement, Dimension will, following consummation of the acquisition, become a wholly owned subsidiary of REGENXBIO
Regenxbio to buy battered Dimension for gene therapies biospectrumasia
August 29, 2017
Under the terms of the definitive agreement, Dimension will, following consummation of the acquisition, become a wholly owned subsidiary of REGENXBIO
Regenxbio to buy battered Dimension for gene therapies fiercebiotech
August 28, 2017
Dimension is selling after posting weak data on its lead candidate.
Silverstein-backed startup will test gene therapy for Parkinson's fiercebiotech
August 10, 2017
Prevail Therapeutics will use Regenxbio's gene therapy vector technology.

Previous page 1 2 Next page